Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249900 | 0.84 | BRD4 (0.48) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL5517077 | 0.79 | HTR2C (0.64) | HTR2CCACNA1GCACNA1HCACNA1IPSEN1 | |
| SCHEMBL10053573 | 0.79 | HTR2C (0.64) | HTR2CCACNA1GCACNA1HCACNA1IPSEN1 | |
| SCHEMBL5517082 | 0.79 | HTR2C (0.64) | HTR2CCACNA1GCACNA1HCACNA1IPSEN1 | |
| SCHEMBL14209521 | 0.79 | HTR2C (0.57) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31114244 | 0.79 | HTR2C (0.57) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19271743 | 0.77 | HTR2C (0.55) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21872248 | 0.77 | HTR2C (0.55) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30523584 | 0.77 | HTR2C (0.55) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14880766 | 0.75 | HTR2C (0.53) | HTR2CPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951709-B1 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8003653-B2 | Imidazolidinone compounds useful as β-secretase inhibitors for the treatment of Alzheimer's disease | Merck. Sharp & Dohme Corp. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090111832-A1 | Imidazolidinone Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2009-04-30 | — | — | US | disclosed |
| EP-1951709-A2 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058862-A2 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111832-A1 | Imidazolidinone Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | HTR2C 4144/4885CACNA1G 2487/4885CACNA1H 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.